In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.

Fresh off winning a Nobel Prize last year, and previously tackling antibodies and peptides, the University of Washington’s ...

Amanda Hansen leaves her home near Phoenix to catch a flight to Austin. On Monday mornings she checks into Dell Children's Medical Center to participate in a clinical trial to try to save her ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

Allergy medications not doing the job this season? Experts explain why allergy immunotherapy may be the newest answer to ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biomedical engineers at Duke University have demonstrated a new synthetic approach that turbocharges bacteria into producing ...

With threats of avian flu and lead poisoning, biologists are working overtime to care for a species that nearly went extinct.

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Republican lawmakers have criticized institutions for allegedly misusing taxpayer money, citing cases such as the 2020 settlement in which the Scripps Research Institute agreed to pay $10 million for ...